Răzvan Cristescu

12.7k total citations · 1 hit paper
107 papers, 3.6k citations indexed

About

Răzvan Cristescu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Răzvan Cristescu has authored 107 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 29 papers in Cancer Research. Recurrent topics in Răzvan Cristescu's work include Cancer Immunotherapy and Biomarkers (42 papers), Cancer Genomics and Diagnostics (29 papers) and Gastric Cancer Management and Outcomes (13 papers). Răzvan Cristescu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (42 papers), Cancer Genomics and Diagnostics (29 papers) and Gastric Cancer Management and Outcomes (13 papers). Răzvan Cristescu collaborates with scholars based in United States, South Korea and Japan. Răzvan Cristescu's co-authors include Martin Vetterli, Baltasar Beferull‐Lozano, Jared Lunceford, Mark Ayers, Andrey Loboda, Deepti Aurora-Garg, Yung‐Jue Bang, Deepak Ganesan, Julie Kobie and Patrick A. Ott and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Răzvan Cristescu

100 papers receiving 3.5k citations

Hit Papers

T-Cell–Inflamed Gene-Expression Profile, Programmed Death... 2018 2026 2020 2023 2018 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
    2018 656 citations Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Răzvan Cristescu United States 31 1.8k 1.0k 776 605 559 107 3.6k
Weijia Fang China 32 1.7k 0.9× 715 0.7× 395 0.5× 1.1k 1.8× 592 1.1× 139 4.2k
Mukund Seshadri United States 29 987 0.5× 979 0.9× 198 0.3× 1.1k 1.8× 324 0.6× 109 3.7k
Junli Wu China 25 781 0.4× 226 0.2× 249 0.3× 456 0.8× 272 0.5× 93 2.0k
Xavier Leroy France 45 681 0.4× 3.0k 2.9× 437 0.6× 2.1k 3.5× 599 1.1× 297 8.4k
David Salomon United States 26 1.2k 0.7× 547 0.5× 160 0.2× 1.5k 2.5× 252 0.5× 67 3.8k
Marc S. Mendonca United States 30 504 0.3× 761 0.7× 1.5k 1.9× 1.1k 1.8× 81 0.1× 104 3.9k
Mark Kaminski United States 44 2.7k 1.5× 1.2k 1.2× 135 0.2× 1.3k 2.2× 1.2k 2.2× 193 8.1k
Xian Zhou China 37 2.0k 1.1× 882 0.9× 91 0.1× 1.0k 1.7× 198 0.4× 213 6.1k
Sihua Wang China 25 223 0.1× 194 0.2× 343 0.4× 500 0.8× 281 0.5× 101 1.9k
Dorothea Wagner Germany 28 1.8k 1.0× 2.2k 2.1× 134 0.2× 794 1.3× 222 0.4× 152 4.4k

Countries citing papers authored by Răzvan Cristescu

Since Specialization
Citations

This map shows the geographic impact of Răzvan Cristescu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Răzvan Cristescu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Răzvan Cristescu more than expected).

Fields of papers citing papers by Răzvan Cristescu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Răzvan Cristescu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Răzvan Cristescu. The network helps show where Răzvan Cristescu may publish in the future.

Co-authorship network of co-authors of Răzvan Cristescu

This figure shows the co-authorship network connecting the top 25 collaborators of Răzvan Cristescu. A scholar is included among the top collaborators of Răzvan Cristescu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Răzvan Cristescu. Răzvan Cristescu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Janjigian, Yelena Y., Michael Cecchini, Kohei Shitara, et al.. (2025). Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies. JCO Precision Oncology. 9(9). e2400456–e2400456. 1 indexed citations
2.
Tekin, Cumhur, et al.. (2024). Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer. Journal of Gynecologic Oncology. 35(6). e105–e105. 7 indexed citations
3.
Kudo, Masatoshi, Ann‐Lii Cheng, Philippe Merle, et al.. (2024). Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.. Journal of Clinical Oncology. 42(16_suppl). 4109–4109. 1 indexed citations
4.
Motzer, Robert J., Camillo Porta, Masatoshi Eto, et al.. (2024). Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.. Journal of Clinical Oncology. 42(16_suppl). 4504–4504. 7 indexed citations
5.
Cai, Chen, Elisha J. Dettman, Wei Zhou, et al.. (2024). Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study. Future Oncology. 20(31). 2357–2370.
6.
Motzer, Robert J., Camillo Porta, Masatoshi Eto, et al.. (2024). Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma. Annals of Oncology. 36(4). 375–386. 6 indexed citations
7.
Shao, Changxia, Heng Zhou, Elisha J. Dettman, et al.. (2023). Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors. JCO Precision Oncology. 7(7). e2300195–e2300195. 1 indexed citations
8.
9.
Lee, Keun‐Wook, Eric Van Cutsem, Yung‐Jue Bang, et al.. (2022). Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. Clinical Cancer Research. 28(16). 3489–3498. 55 indexed citations
10.
Haddad, Robert I., Tanguy Y. Seiwert, Laura Q.M. Chow, et al.. (2022). Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 10(2). e003026–e003026. 54 indexed citations
11.
Cristescu, Răzvan, Michael Nebozhyn, Chunsheng Zhang, et al.. (2021). Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types. Clinical Cancer Research. 28(8). 1680–1689. 40 indexed citations
12.
13.
Ayers, Mark, Michael Nebozhyn, Răzvan Cristescu, et al.. (2018). Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy. Clinical Cancer Research. 25(5). 1564–1573. 27 indexed citations
14.
Ott, Patrick A., Yung‐Jue Bang, Sarina A. Piha‐Paul, et al.. (2018). T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology. 37(4). 318–327. 656 indexed citations breakdown →
15.
Guertin, Amy D., Jennifer O’Neil, Alexander Stoeck, et al.. (2016). High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide. Molecular Cancer Therapeutics. 15(8). 1998–2008. 16 indexed citations
16.
O’Neil, Jennifer, Yair Benita, Igor Feldman, et al.. (2016). An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies. Molecular Cancer Therapeutics. 15(6). 1155–1162. 227 indexed citations
17.
Wang, I‐Ming, Andrew J. Bett, Răzvan Cristescu, Andrey Loboda, & Jan ter Meulen. (2011). Transcriptional profiling of vaccine‐induced immune responses in humans and non‐human primates. Microbial Biotechnology. 5(2). 177–187. 26 indexed citations
18.
Cristescu, Răzvan & Martin Vetterli. (2005). On the optimal density for real-time data gathering of spatio-temporal processes in sensor networks. Information Processing in Sensor Networks. 21. 45 indexed citations
19.
Cristescu, Răzvan, et al.. (2005). Power Control for Target Tracking in Sensor Networks. Infoscience (Ecole Polytechnique Fédérale de Lausanne). 12 indexed citations
20.
Cristescu, Răzvan & S.D. Servetto. (2001). Flow control for multiple access queues. Infoscience (Ecole Polytechnique Fédérale de Lausanne). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weijia Fang Breakdown of academic impact, for papers by Mukund Seshadri Breakdown of academic impact, for papers by Junli Wu Breakdown of academic impact, for papers by Xavier Leroy Breakdown of academic impact, for papers by David Salomon Breakdown of academic impact, for papers by Marc S. Mendonca Breakdown of academic impact, for papers by Mark Kaminski Breakdown of academic impact, for papers by Xian Zhou Breakdown of academic impact, for papers by Sihua Wang Breakdown of academic impact, for papers by Dorothea Wagner
Rankless by CCL
2026